Working… Menu
Trial record 1 of 3 for:    CRISPR | Pennsylvania, United States
Previous Study | Return to List | Next Study

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03399448
Recruitment Status : Recruiting
First Posted : January 16, 2018
Last Update Posted : March 4, 2019
Parker Institute for Cancer Immunotherapy
Tmunity Therapeutics
Information provided by (Responsible Party):
University of Pennsylvania

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2033
Estimated Study Completion Date : January 2033